Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study

Aihara M., Ropo A., Lu F., Kawata H., Iwata A., Odani-Kawabata N., Shams N.

2020
Japanese Journal of Ophthalmology

View publication

Therapeutic Area

Glaucoma
Categories

Clinical development

Affiliations

Ophthalmology, University of Tokyo, Tokyo, Japan; Santen Oy, Vantaa, Finland; Santen Inc., Emeryville, CA, United States; Santen Pharmaceutical Co., Ltd, Osaka, Japan

Related Publications

Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma: 2-year Results from a Randomized, Multicenter Study

Panarelli JF, Moster MR, Garcia-Feijoo J, Flowers BE, Baker ND, Barnebey HS, Grover DS, Khatana AK, Lee B, Nguyen T, Stiles MC, Sadruddin O, Khaw PT.

Omidenepag Isopropyl in Latanoprost Low/Non-Responders with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3, Non-Randomized, Two-Phase, Open-Label Study

Panarelli JF, Bowden EC, Tepedino ME, Odani-Kawabata N, Pei Z, McLaurin EB, Ropo A.

The Development of a SIBS Shunt to Treat Glaucoma

Pinchuk L.

View all Glaucoma publications

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022